ArticleMicrobiology spectrum2025
The new gold rush in clinical diagnostics: from standard laboratory assays to fast and accurate point-of-care (POC) methods.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gold and silver nanoparticles for safe and effective biomedical applications.Discover nano · 2026Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Integrating two point-of-care (POC)-amenable technologies, namely, multiple cross displacement amplification (MCDA) and gold nanoparticle-based lateral flow biosensors (AuNPs-LFB), has demonstrated excellent detection of hepatitis B virus (HBV) and hepatitis C virus (HCV). In a recent study, Zhang et al. (H. Zang, Y. Shi, Z. Wu, Q. Zhao, et al., Microbiol Spectr 13:e01738-24, 2025, https://doi.org/10.1128/spectrum.01738-24) developed a novel, single-tube, multiplex MCDA-AuNPs-LFB assay that targets the HBV S gene and the HCV 5'-UTR region. The assay operates under isothermal conditions at 64°C for 35 min, and the AuNPs-LFB assay permits a visual interpretation of results. This platform achieves an analytical sensitivity comparable to lab-based quantitative PCR but with shorter turnaround time, reduced cost, operational simplicity, and undetectable cross-reactivity to anatomically relevant, non-target pathogens, making it highly suitable for decentralized POC diagnostic applications. The success of hybrid systems in simplifying nucleic acid testing while increasing portability indicates a potential transition in clinical diagnosis from centralized tech-centered labs to local clinics, field testing, and even home care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.